Roche chairman Christoph Franz offers glint of hope after tiragolumab fail — report
On the heels of a bad week for Roche and its TIGIT tiragolumab, board chair Christoph Franz is trying to look on the bright side.
In an interview with Reuters, Franz said the company has enough coming down the pipeline to make up for tiragolumab’s second straight Phase III flop.
Roche revealed on Wednesday that the drug flunked on a co-primary progression-free survival endpoint in combination with Tecentriq in a study for PD-L1 high non-small cell lung cancer patients — sending $RHHBY stock plummeting more than 8%.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.